Delek US EVP sells 10,000 DK shares under plan

Delek US Holdings executive Reuven Spiegel reported an open-market sale of company stock.

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Delek US Holdings executive Reuven Spiegel reported an open-market sale of company stock. On May 18, 2026, he sold 10,000 shares of Delek US Holdings common stock at $44.36 per share. After this transaction, he directly holds 48,372 shares of common stock.

The filing notes the sale was executed under a Rule 10b5-1 trading plan, which is a pre-arranged program intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Spiegel Reuven

Role EVP, Special Projects

Sold 10,000 shs ($444K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$44.36	$444K

Holdings After Transaction: Common Stock — 48,372 shares (Direct)

Footnotes (1)

F1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Key Figures

Shares sold: 10,000 shares Sale price: $44.36 per share Shares held after transaction: 48,372 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale of common stock on May 18, 2026

Sale price $44.36 per share Price for the 10,000 common shares sold

Shares held after transaction 48,372 shares Direct ownership following the reported sale

Net shares sold 10,000 shares Net-sell direction per transaction summary

Key Terms

Rule 10b5-1, open-market sale, Form 4, affirmative defense conditions

4 terms

Rule 10b5-1 regulatory

"This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

affirmative defense conditions regulatory

"intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DK executive Reuven Spiegel report?

EVP Reuven Spiegel reported an open-market sale of 10,000 shares of Delek US Holdings common stock. The sale occurred at $44.36 per share and was disclosed on a Form 4 insider trading report with the SEC.

At what price did Reuven Spiegel sell Delek US (DK) shares?

He sold 10,000 Delek US Holdings common shares at $44.36 per share. This was an open-market transaction, meaning the shares were sold through normal market trading rather than via a private agreement or option exercise.

How many Delek US (DK) shares does Reuven Spiegel hold after the sale?

Following the reported sale, Reuven Spiegel directly holds 48,372 shares of Delek US Holdings common stock. This post-transaction holding reflects his remaining direct ownership position as shown in the Form 4 filing.

Was the DK insider sale by Reuven Spiegel under a Rule 10b5-1 plan?

Yes. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged programs designed to satisfy the affirmative defense conditions of Rule 10b5-1(c) for insider transactions.

What role does Reuven Spiegel hold at Delek US Holdings (DK)?

Reuven Spiegel serves as an officer of Delek US Holdings with the title EVP, Special Projects. His status as an executive officer means his trades in company stock must be reported to the SEC on Form 4.

How many DK shares did Reuven Spiegel sell in this Form 4 filing?

He sold 10,000 shares of Delek US Holdings common stock in this transaction. The Form 4 identifies the trade as an open-market sale at a price of $44.36 per share, categorized under transaction code “S.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/20/2026 - 09:02 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spiegel Reuven

(Last)

(First)

(Middle)

310 SEVEN SPRINGS WAY

SUITE 500

(Street)

BRENTWOOD

TENNESSEE

37027

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Delek US Holdings, Inc. [ DK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Special Projects

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		S		10,000⁽¹⁾	D	$44.36	48,372	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Remarks:

	/s/ Misty Lavender, Attorney in Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR